Selective NaV1.8 Blockers for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NaV inhibitors have a poor therapeutic window due to their lack of isoform selectivity, leading to adverse events. There is a need for more potent and selective NaV1.8 blockers to effectively treat pain without inducing common adverse effects.
Innovation Solution
Development of specific compounds that selectively target NaV1.8 channels, potentially in the form of pharmaceutical compositions, to inhibit voltage-gated sodium channels and treat various pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NaV inhibitors are used, then pain relief is achieved, but adverse effects increase due to lack of isoform selectivity
Solution Approach 1:
The patent applies local quality by developing compounds with selective affinity for specific NaV isoforms (particularly NaV1.8) rather than acting as non-selective inhibitors. This isoform-selective approach allows the drug to exert its analgesic effect at the specific site of pain transmission while avoiding off-target effects on other sodium channel isoforms expressed in different tissues, thereby reducing adverse effects while maintaining pain relief effectiveness.
2Reliability
If existing NaV inhibitors are used, then pain signaling is reduced, but therapeutic window is poor leading to side effects
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical structure of NaV inhibitor compounds to optimize their pharmacological properties. Through structure-activity relationship (SAR) analysis, the patent identifies specific molecular modifications that enhance selectivity for NaV1.8 channels while maintaining or improving binding affinity. This chemical parameter optimization results in compounds with a widened therapeutic window, achieving effective pain signaling inhibition at doses that minimize side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective NaV1.8 blockers demonstrate enhanced potency and reduced adverse effects, effectively addressing chronic, neuropathic, and inflammatory pain conditions while minimizing side effects.
Implementation Method 1
Voltage-gated sodium channels (NaV's) are involved in pain signaling. NaV's are biological mediators of electrical signaling as they mediate the rapid upstroke of the action potential of many excitable cell types
Data Source
AI summary
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.